EyePoint Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview

EyePoint

06/11/2024 14:10

* EyePoint Pharmaceuticals Inc  EYPT.OQ   EYPT.O  is
expected
to show a fall in quarterly revenue when it reports  results on
November 8 (estimated) for the period ending September 30 2024
    * The Watertown Massachusetts-based  company is expected to
report
a 31.4% decrease in revenue to $10.423 million from $15.2
million a year ago, according to the mean estimate from 11
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for EyePoint Pharmaceuticals
Inc
is for a loss of 55 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for EyePoint
Pharmaceuticals Inc is $32.50​, above​ its last closing price
of $11.61. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.51       -0.52      -0.58     Missed  -10.5
 Mar. 31 2024  -0.42       -0.42      -0.55     Missed  -32.2
 Jan. 1 0001   -0.46       -0.49      -0.33     Beat    32.1​
 Jan. 1 0001   -0.54       -0.51      -0.33     Beat    35.7
 ​​Jun.        0.68        0.60       -0.61     Missed  -201.9
 30 2023                                                
 Mar. 31 2023  -0.68       -0.68      -0.56     Beat    18​
 Dec. 31 2022  -0.61       -0.61      -1.16     Missed  -90.2
 Sep. 30 2022  -0.69       -0.70      -0.49     Beat    29.6
 This summary was machine generated November 6 at 14:09 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)